Showing 12,421 - 12,440 results of 13,825 for search '"Academy"', query time: 0.08s Refine Results
  1. 12421
  2. 12422

    Hydrophobic and Hydrophilic IOLs in Patients with Uveitis – A Randomised Clinical Trial by Pålsson S, Schuborg C, Sterner B, Andersson Grönlund M, Zetterberg M

    Published 2025-02-01
    “…Sara Pålsson,1,2 Claes Schuborg,2,3 Bertil Sterner,1,2 Marita Andersson Grönlund,1,4 Madeleine Zetterberg1,2 1Department of Clinical Neuroscience/Ophthalmology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 2Region Västra Götaland, Sahlgrenska University Hospital, Department of Ophthalmology, Mölndal, Sweden; 3Guldhedskliniken, Gothenburg, Sweden; 4Department of Ophthalmology, Faculty of Medicine and Health, Örebro University, Örebro, SwedenCorrespondence: Madeleine Zetterberg, Sahlgrenska University Hospital, Department of Ophthalmology, Mölndal, SE 431 80, Sweden, Tel +46 31 33 43 31 50, Fax +46 31 41 29 04, Email madeleine.zetterberg@vgregion.sePurpose: To compare inflammatory response, visual acuity, and complications of two intraocular lenses (IOLs) in patients with and without uveitis.Setting: Tertiary referral centre at Sahlgrenska University Hospital/Mölndal, Sweden.Design: Prospective randomised controlled trial.Patients and Methods: Patients with and without uveitis eligible for cataract surgery were randomised to receive a hydrophobic or a hydrophilic square-edged intraocular lens (IOL). …”
    Get full text
    Article
  3. 12423
  4. 12424
  5. 12425
  6. 12426
  7. 12427
  8. 12428
  9. 12429
  10. 12430
  11. 12431
  12. 12432
  13. 12433
  14. 12434
  15. 12435
  16. 12436
  17. 12437
  18. 12438
  19. 12439
  20. 12440

    Simultaneous Determination of Multiple Acid-Suppressing Drugs by UPLC-MS/MS Method and Application for Pharmacokinetics Study by Li X, Liu S, Yu M, Xi W, Wu X, Liu D, Liu A, Wang H

    Published 2025-02-01
    “…Xiuqi Li,1,* Shupeng Liu,1,* Mengyang Yu,1 Wanlin Xi,1 Xiaofei Wu,1 Dan Liu,2 Aijing Liu,1 Hongyun Wang1 1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China; 2School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hongyun Wang, Email wanghy@pumch.cnBackground: Proton pump inhibitors (PPIs) and potassium competitive acid blockers (P-CABs) are widely used to treat acid-related diseases (ARDs). …”
    Get full text
    Article